News from impel neuropharma A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Oct 08, 2020, 08:00 ET Impel NeuroPharma Presents Data From Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine At 2020 Migraine Trust Virtual Symposium
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jun 30, 2020, 13:10 ET Impel NeuroPharma Announces Publication of Positive Results of SNAP 101 Study for INP105 for the Treatment of Acute Agitation in The Journal of Clinical Psychiatry
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jun 15, 2020, 07:30 ET Impel NeuroPharma Presents Data From INP104 Clinical Program In Acute Migraine At The 2020 American Headache Society (AHS) Virtual Annual Scientific Meeting
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jun 10, 2020, 10:00 ET Impel NeuroPharma Announces Primary Objectives Met In Pivotal Phase 3 Registration Study Of INP104 For The Treatment Of Acute Migraine
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
May 05, 2020, 08:00 ET Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams' Role Expanded To Chairman And CEO
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jan 16, 2020, 11:40 ET Impel NeuroPharma Announces Appointment of Sheena K. Aurora, MD, As Vice President of Medical Affairs - Migraine Franchise
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jan 09, 2020, 16:01 ET Impel NeuroPharma Announces Appointment Of Adrian Adams As Chairman Of The Board Of Directors
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Nov 20, 2019, 11:49 ET Impel NeuroPharma Announces Publication Of Narrative Review In The Journal Headache Supporting Need For Novel Formulations Of Dihydroergotamine (DHE) In Addressing Acute Treatment Of Migraine
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Oct 17, 2019, 12:45 ET Impel NeuroPharma Announces Appointment Of Diane Wilfong To Board Of Directors
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Sep 05, 2019, 13:34 ET Impel NeuroPharma to Present Data From INP104 Clinical Program at the 19th Congress of the International Headache Society
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Sep 03, 2019, 13:12 ET Impel NeuroPharma Announces Last Patient Enrolled In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jul 10, 2019, 15:26 ET Impel NeuroPharma to Present Data From INP104 Clinical Program at the 61st Annual Scientific Meeting of the American Headache Society
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
Jun 26, 2019, 08:00 ET Impel NeuroPharma Appoints John Leaman as Chief Financial Officer
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients...
May 17, 2019, 12:20 ET Impel Neuropharma to Present Data at 2019 American Psychiatric Association (APA) Annual Meeting
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock...
Apr 30, 2019, 10:32 ET Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting
Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapeutics for...
Feb 19, 2019, 08:00 ET Impel NeuroPharma Appoints Jennifer L. Berman As Vice President Of Marketing
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
Jan 06, 2019, 10:00 ET Impel Neuropharma Announces Positive Phase 1 Trial For INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on innovative therapies for the treatment of central nervous...
Nov 07, 2018, 08:00 ET Impel NeuroPharma Appoints Ellen A. Lubman As Chief Business Officer
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system...
Aug 29, 2018, 08:00 ET Impel NeuroPharma Annouces First Subject Dosed In Phase 1 Trial Evaluating INP105 For The Treatment Of Acute Agitation In Bipolar I Disorder And Schizophrenia
Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS)...
Aug 22, 2018, 08:00 ET Impel Neuropharma Announces First Patient Dosed In Phase 3 Trial Evaluating INP104 For The Treatment Of Acute Migraine Headache
Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS)...
Jul 16, 2018, 08:45 ET Impel NeuroPharma Strenthens Leadership Team With Appointment Of Lynn C. Gold As Senior Vice President Of Regulatory Affairs
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
Jun 26, 2018, 12:00 ET Impel NeuroPharma To Present New Data On INP104 For Treatment Of Acute Migraine At 2018 Annual American Headache Society Meeting
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
May 31, 2018, 08:00 ET Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson's Disease OFF Episodes
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
Feb 07, 2018, 09:45 ET Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
Oct 31, 2017, 08:00 ET Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache
Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on therapies for the treatment of central nervous system (CNS)...
